Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on ADMA Biologics (NASDAQ:ADMA) and raises the price target from $15 to $20.
August 09, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on ADMA Biologics and raises the price target from $15 to $20.
The raised price target from $15 to $20 and the maintained Overweight rating by a reputable analyst is likely to positively impact ADMA Biologics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100